ZCM
STLN

Zebra Capital Management’s Starling Oncology STLN Stock Holding History

Zebra Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,484
Closed -$127K – 87
2022
Q3 		$127K Buy
+27,484
New +$162K 0.48% 65

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Zebra Capital Management's STLN Position: Q4 2022 in Review

Zebra Capital Management sold out of Starling Oncology (STLN) in Q4 2022, closing a stake of 27,484 shares — an estimated $127K sold.

Zebra Capital Management first reported a position in STLN in Q3 2022 and held it in 1 quarter. The position peaked at $127K in Q3 2022. 41 funds tracked by Wall St. Rank hold STLN as of Q4 2022.

  • Zebra Capital Management reported no remaining Starling Oncology position as of Q4 2022 after selling out during the quarter.
  • Zebra Capital Management sold 27,484 Starling Oncology shares in Q4 2022, an estimated $127K.
  • Zebra Capital Management first reported a position in Starling Oncology in Q3 2022 and held it in 1 quarter.
  • Zebra Capital Management's Starling Oncology position peaked at $127K in Q3 2022.
  • 41 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2022.

Based on Zebra Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.